药械

订阅

MedSci主页 / 所有栏目 / 药械

PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗

2020-03-06 不详 MedSci原创

PureTech纤维化和炎症淋巴水肿LYT-100临床试验首位参与者
关注

PureTech宣布，其针对淋巴水肿和其他纤维化疾病的候选药LYT-100的一项临床研究，首位参与者已经开始接受治疗。

PureTech宣布，其针对淋巴水肿和其他纤维化疾病的候选药LYT-100的一项临床研究，首位参与者已经开始接受治疗。

该试验旨在评估LYT-100在健康受试者中的安全性、耐受性和药代动力学（PK）特性。

Memorial Sloan Kettering癌症中心Babak Mehrara说，这些疾病导致"严重的残疾，但很少有有意义的治疗选择，其中大多数是使用压缩和物理疗法以控制肿胀。LYT-100旨在通过减少纤维化和炎症并恢复淋巴功能来解决淋巴水肿，我相信它具有巨大的潜力，可作为治疗淋巴水肿的候选疗法。"

被评估的药物是口服的小分子候选药物，称为deupirfenidone，已显示出临床前的抗纤维化和抗炎活性。

淋巴水肿是一种慢性疾病，其特征是由于淋巴液的积聚和炎症、纤维化和脂肪沉积，导致身体（通常是手臂或腿）严重肿胀。

目前FDA尚未批准可治疗淋巴水肿的药物，淋巴水肿是一种导致疼痛、进行性的慢性疾病，仅在美国就影响约100万人，其中包括约50万乳腺癌幸存者。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2021-10-28 ms4000001344250544

    请问现在这个药到几期，患者可以参加临床试验吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2021-09-08 146aa29fm11暂无昵称

    期待，各位科学家的好消息😀

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-08-30 ysjykql

    #RET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-07-08 waiwai3030

    #纤维化和炎症#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-10-07 ms5768352621950538

    #首位参与者#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-04-20 minlingfeng

    #PureTech#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-08-05 shock_melon

    #TEC#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-03-09 杨帆7792

    期待 造福千万患者

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-03-08 小华子

    #水肿#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1064574, encodeId=5d5910645e451, content=请问现在这个药到几期，患者可以参加临床试验吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e525539378, createdName=ms4000001344250544, createdTime=Thu Oct 28 08:48:49 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015533, encodeId=915c101553354, content=期待，各位科学家的好消息😀, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03495156813, createdName=146aa29fm11暂无昵称, createdTime=Wed Sep 08 02:22:20 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Aug 30 22:49:00 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804462, encodeId=6ebf180446235, content=<a href='/topic/show?id=6b49e72303d' target=_blank style='color:#2F92EE;'>#纤维化和炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77230, encryptionId=6b49e72303d, topicName=纤维化和炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Wed Jul 08 18:49:00 CST 2020, time=2020-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821140, encodeId=ee2b1821140c9, content=<a href='/topic/show?id=ef4d101296c5' target=_blank style='color:#2F92EE;'>#首位参与者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101296, encryptionId=ef4d101296c5, topicName=首位参与者)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Wed Oct 07 21:49:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950288, encodeId=884319502883e, content=<a href='/topic/show?id=8dbe1489413' target=_blank style='color:#2F92EE;'>#PureTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14894, encryptionId=8dbe1489413, topicName=PureTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 20 00:49:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Wed Aug 05 10:49:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380254, encodeId=4e073802541b, content=期待 造福千万患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Mon Mar 09 21:47:03 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333459, encodeId=639513334595a, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366597, encodeId=fb5f136659ecd, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Sun Mar 08 01:49:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-03-08 dangious

    #淋巴水肿#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

罗氏交易的消息提振了PureTech的股价

总部位于英国的临床阶段生物制药公司PureTech Health的股价得到提振，此前有消息称，罗氏已签署协议，以推进其exosome平台技术，这笔交易可能价值逾10亿美元。PureTech表示，其基于牛奶外泌体的技术"设计独特，可促进复杂有效载荷的口服"，包括核酸，多肽和小分子。这些外泌体被认为是通过淋巴循环传播的，有可能以新的方式靶向免疫细胞。根据协议，PureTech Health将获得高达3

PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景

PureTech宣布了其毒蕈碱受体激动剂xanomeline的口服制剂KarXT 在II期试验治疗精神分裂症患者的急性精神疾病的积极结果。与安慰剂相比，KarXT在阳性和阴性综合症状量表（PANSS）总分中显示出统计学上显着且具有临床意义的平均降低。该药物还显示出良好的总体耐受性，并且还观察到PANSS阳性和PANSS阴性评分的次要终点在统计学上显着降低。